Finally we show that this robust AWT1 epigenetic signature is an excellent marker for discriminating AML from non-diseased peripheral blood and that this hypermethylation signature can accurately track disease progression, differentiating patients who relapse from those achieving complete remission after allogeneic hematopoietic stem cell transplantation (SCT). This evidence concerns the gene WT1 and acute myeloid leukemia.